江蘇吳中(600200.SH):擬投建江蘇吳中醫藥集團研發及產業化基地一期項目
格隆匯1月14日丨江蘇吳中(600200.SH)公佈,近日,公司全資子公司江蘇吳中醫藥集團有限公司(“吳中醫藥”)與蘇州吳中經濟技術開發區招商局在蘇州市簽署了《用地項目投資協議書》,吳中醫藥將在計劃取得的113.27畝土地上建設江蘇吳中醫藥集團研發及產業化基地一期項目,項目建設總投資額約17.28億元人民幣。
項目建設內容:主要建設內容包括綜合辦公中心、生物創新中心、質檢研發中心、注射劑樓、口服制劑樓、綜合製劑樓、倉庫及環保處理設施等。
醫藥板塊為公司核心業務板塊,根據蘇州市吳中經濟開發區規劃調整,吳中醫藥中凱生物製藥廠已實施拆遷,後續待醫藥新基地建設完成後,吳中醫藥蘇州製藥廠也將整體搬遷至醫藥新基地。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.